Top Health Tech Companies in Hyderabad (64)

Investor Backing & Capital Strength: A $90M Series C in May 2025—corroborated by trade press—was secured to expand the AI-driven platform and scale operations. Additional equity raised in 2024 and total capital around $200M signal strong investor support for growth.

Product Line Growth: In September 2025 the company launched a Payment Integrity suite and acquired ZignaAI, extending beyond utilization management into claims/payment accuracy. Subsequent 2026 updates expanded the platform into appeals, care management, claims operations, and quality.

Market Expansion: Payer materials indicate Cohere Health reviews Humana prior authorization requests nationwide, with HealthPartners documents in 2025–2026 showing adoption beyond Humana. Company-reported operating scale (600k+ providers, millions of requests) and added plan wins through 2026 suggest a broader payer footprint.

Market Expansion: Headcount and footprint are described as rising to more than 15,000 employees across 40-plus offices, alongside concrete new sites in Hyderabad and a completed Chicago buildout—signals of geographic and capacity expansion. These moves indicate confidence in demand across key delivery hubs.

Innovation-Driven Growth: A dedicated Platforms & Products unit, the ZAIDYN portfolio, and AI-agent initiatives point to sustained investment in productized, AI-enabled offerings. Capability-deepening acquisitions (Digital Additive in 2024 and Torrent Consulting in 2025) further strengthen CRM and multi‑cloud life‑sciences solutions.

Strategic Partnerships: An expanded Salesforce collaboration around Agentforce and recognition as Databricks 2025 Life Sciences Partner of the Year suggest momentum in data/AI ecosystems. These alliances position the firm to capture spend where CRM, data, and AI converge in healthcare and life sciences.

Strong Revenue Growth: Consolidated revenues increased from $253 billion in 2024 to $270.6 billion in 2025, with quarterly gains such as Q4 2025 up 8% year over year. Growth was led primarily by Optum Rx and supported by steady contributions from Optum Insight.

Market Expansion: Expansion through acquisitions such as Holston Medical Group (August 2025) and Alegeus (July 2026), alongside earlier combinations like Change Healthcare and Atrius Health, broadened capabilities across care, pharmacy, and payments. These moves extend Optum’s platform into adjacent services and operating domains.

Diversified Revenue Streams: A multi-segment model—Rx, Insight, and Health—helps sustain aggregate growth even as individual lines vary, with pharmacy and technology businesses offsetting care-delivery softness. Parent-company commentary continuing to frame Optum as a growth engine and raising 2026 guidance underscores the benefit of this portfolio effect.

Strong Revenue Growth: Total revenue increased to $255.9M in 2025 with software up and drug‑discovery more than doubling, while operating expenses declined year over year. Early 2026 also showed momentum, with first‑half revenue modestly higher and Q2 posting year‑over‑year growth.

Strategic Partnerships: New and expanded agreements—such as Bristol Myers Squibb deploying Bunsen and a July 2026 discovery collaboration with Simcere—broaden platform use and collaboration optionality. The Lilly/Ajax transaction also validated the model and supported a higher 2026 drug‑discovery outlook.

Product Line Growth: The introduction of Bunsen, an agentic AI co‑scientist, expands the software portfolio and is being deployed at scale within BMS. This product push complements growth in ACV and broader platform adoption.

Strong Revenue Growth: Sales growth is described as strong, with 2025 net sales up at constant exchange rates and Q4 showing further acceleration, indicating momentum into 2026.

Profitability: Earnings expansion is described as outpacing sales growth in 2025, and 2026 guidance indicates continued profitable expansion with EPS growing slightly faster than sales.

Product Line Growth: Newer launches are scaling rapidly, with notable growth in recent pharma launches and contributions from products beyond the flagship franchise, helping broaden growth drivers.

Strong Market Position & Advantage: Feedback suggests ABC holds a leading position for enterprise gyms and payments at scale, reinforced by multi-platform coverage across operators. External mentions of leadership and large-scale operations indicate durable competitive presence in core segments.

Market Expansion: Feedback suggests ABC has expanded globally with usage in over 100 countries and strengthened regional presence in Latin America via EVO. Partnerships with major franchises and international brands further extend its footprint.

Innovation-Driven Growth: Feedback suggests ongoing product innovation—AI-powered operating infrastructure, new CRM/BI releases, and deeper cross-product integrations—is propelling growth. Regular launches across Ignite, Glofox, Trainerize, and EVO point to a forward-leaning roadmap.

Strong Market Position & Advantage: Industry and company materials indicate ResMed is the leading player in global sleep‑apnea devices and masks, supported by scale and a large connected ecosystem (AirView/myAir). Philips’ U.S. consent decree and extended remediation have provided a multi‑year window that reinforced ResMed’s relative momentum.

Strong Revenue Growth: Recent quarters show continued year‑over‑year revenue growth with margin expansion, driven by device demand and recurring masks/accessories. Management commentary and investor materials point to sustained momentum through FY2026 to date.

Diversified Revenue Streams: A large installed base of connected devices underpins recurring resupply revenue and remote monitoring workflows. Ownership of Brightree and MatrixCare adds out‑of‑hospital software that complements the core hardware franchise.

Investor Backing & Capital Strength: Growth investments from New Mountain Capital (2019) and the Blue Venture Fund (2020) provide capital support for expansion. This backing aligns with subsequent acquisitions and capability build-outs from 2017–2022.

Innovation-Driven Growth: Launch of a healthcare agentic AI suite in 2026 and HFS placement as an “Enterprise Innovator” with providers indicate active investment in new, differentiated capabilities. Repeated Everest Group recognitions across cloud/data/AI signal ongoing momentum on modern stacks.

Market Expansion: Opening a U.S. innovation hub in Princeton, NJ (September 2025) signals geographic build-out and deeper client engagement in a key market. A multi-country footprint across the U.S., U.K., Canada, Romania, Armenia, and India underscores broader expansion.

Strong Market Position & Advantage: Company materials and third‑party recognition portray a fully integrated CRO/CCO with leadership status, including widespread involvement in recent FDA/EMA novel therapies and recognition as a leading pharmacovigilance provider.

Strategic Partnerships: Recent collaborations with Microsoft and KX are positioned to enable AI‑driven efficiencies across clinical and commercial operations, with reported improvements in cycle times supporting operational scalability.

Investor Backing & Capital Strength: The 2025 take‑private by investment groups (including Elliott and Veritas) provides financial sponsorship to pursue tech‑enabled growth and operational repositioning.

Investor Backing & Capital Strength: Backers and funding announcements point to a strong capital base, including major investors (e.g., Carlyle, Patient Square) and substantial financing raised. Technology upgrade spend and continued sponsor support indicate capacity to sustain growth investments.

Market Expansion: Global moves and acquisitions show widening reach, with operations across 10+ locations and targeted expansion into the GCC via a strategic investment in Santechture. Add-on deals like Xtend Healthcare increased end-to-end RCM breadth and scale.

Innovation-Driven Growth: AI-powered platforms (e.g., PULSE, VISION) and clinically led analytics are highlighted as growth engines delivering material financial impact for client health systems. Recent technology investments and product launches underpin a tech-forward trajectory.

Strong Market Position & Advantage: Industry recognition in payer quality measurement/reporting and payer‑focused data platforms is consistently cited, supported by long‑running certifications and broad health‑plan adoption. Third‑party benchmarks and awards reinforce a leadership foothold in these core categories.

Strong Revenue Growth: Company communications describe multi‑year double‑digit growth since privatization, alongside statements of expanding customer counts and dataset scale. These signals are presented as outcomes of a shift to a pure‑play cloud platform and continued commercial traction.

Innovation-Driven Growth: The shift to a cloud SaaS/Data platform, addition of AI‑enabled features, and a consolidated application portal indicate an emphasis on product velocity. New solution launches and ongoing enhancements are showcased alongside recognitions tied to specific offerings.